On Monday 26th of October Allogene Therapeutics trades 0 percent unchanged
Allogene Therapeutics (ALLO) shares trade flat at $1.26, down 25% YoY; biotech firm develops allogeneic CAR‑T therapy for blood cancers.
- ALLOGENE THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read